FDA Approves Accord BioPharma’s IMULDOSA for Treating Chronic Inflammatory Conditions
Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., which focuses on oncology, immunology, and critical care therapies, has announced the FDA approval of IMULDOSA (uste ...
Capricor Therapeutics Begins BLA Submission for Deramiocel to Treat DMD Cardiomyopathy
Capricor Therapeutics, a biotechnology company dedicated to developing transformative cell and exosome-based therapeutics for rare diseases, has announced the initiation of its rolling submission proc ...